Content area
Full Text
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis ($NVS) is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.
Novartis confirmed today that in the first half of next year, it expects to close the three transactions it announced on April 22--the sale of its animal health unit to Eli Lilly ($LLY) for $5.4 billion, the sale of most of its vaccines to GlaxoSmithKline ($GSK) for $7.1 billion and the formation of a joint venture with GSK to market over-the-counter products. In a press release, the company said that George Gunn, the division head of Novartis Animal Health, will retire upon the closing of the Lilly deal, and Andrin Oswald, who helmed Novartis Vaccines, will...